Welcome to our dedicated page for YD Bio SEC filings (Ticker: YDESW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to YD Bio Limited (YDESW) SEC filings, including reports that describe its activities as a biopharmaceutical company focused on blood-based cancer detection, stem cell-based therapeutics, exosome-based therapeutics, and the supply of clinical testing drugs for pharmaceutical companies. As a foreign private issuer, YD Bio Limited files annual reports on Form 20-F and current reports on Form 6-K with the U.S. Securities and Exchange Commission.
In its Form 6-K dated September 19, 2025, the company discloses a change in its independent registered public accounting firm, the termination of the engagement of CBIZ CPAs P.C., and the appointment of ARK Pro CPA & Co for the fiscal year ending December 31, 2025. The filing explains that prior audit reports from CBIZ CPAs included an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern, while also noting that there were no disagreements on accounting principles, financial statement disclosure, or auditing scope or procedure that required reference in the audit reports.
Through this filings page, users can review such disclosures, along with other documents like annual Form 20-F reports and additional Form 6-K submissions, to understand YD Bio Limited’s financial reporting, auditor relationships, and governance-related information. The platform offers AI-powered summaries that highlight key points from lengthy filings, helping readers interpret going concern language, auditor changes, and other technical disclosures without needing to read every page in detail.
In addition to narrative reports, this page also surfaces relevant SEC documents that may include information on the company’s biopharmaceutical focus, risk factors, and other regulatory content tied to the YDESW symbol, giving investors and researchers a structured way to review YD Bio Limited’s public reporting history.
YD Bio Limited, a Cayman Islands company listed on the Nasdaq Global Market, files its annual report describing a young, loss-making healthcare business built around cancer blood tests and ophthalmology drugs. As of December 31, 2025, it had 70,789,261 ordinary shares and 15,142,911 warrants outstanding.
The report explains that YD Bio was created through a Business Combination with Breeze Holdings Acquisition Corp. and now owns all shares of YD Biopharma. Management discloses recurring losses, significant negative cash flow and substantial doubt about the company’s ability to continue as a going concern without new financing.
Key risks include dependence on critical IP licenses from EG BioMed and 3D Global, reliance on third‑party manufacturers, heavy revenue concentration in three major customers accounting for about 53.7% of 2025 revenue, and limited public‑company experience in the management team.
The company highlights extensive regulatory and reimbursement uncertainty: its cancer tests are Laboratory Developed Tests, future FDA oversight could change, and commercialization would require complex U.S. and foreign approvals and clinical trials. YD Bio is also exposed to Taiwan‑specific geopolitical and natural disaster risks, intellectual property disputes, potential PFIC and U.S. tax issues, and Nasdaq listing and dilution risks from public and private warrants.
YD Bio Limited, a Cayman Islands company listed on the Nasdaq Global Market, files its annual report describing a young, loss-making healthcare business built around cancer blood tests and ophthalmology drugs. As of December 31, 2025, it had 70,789,261 ordinary shares and 15,142,911 warrants outstanding.
The report explains that YD Bio was created through a Business Combination with Breeze Holdings Acquisition Corp. and now owns all shares of YD Biopharma. Management discloses recurring losses, significant negative cash flow and substantial doubt about the company’s ability to continue as a going concern without new financing.
Key risks include dependence on critical IP licenses from EG BioMed and 3D Global, reliance on third‑party manufacturers, heavy revenue concentration in three major customers accounting for about 53.7% of 2025 revenue, and limited public‑company experience in the management team.
The company highlights extensive regulatory and reimbursement uncertainty: its cancer tests are Laboratory Developed Tests, future FDA oversight could change, and commercialization would require complex U.S. and foreign approvals and clinical trials. YD Bio is also exposed to Taiwan‑specific geopolitical and natural disaster risks, intellectual property disputes, potential PFIC and U.S. tax issues, and Nasdaq listing and dilution risks from public and private warrants.
YD Bio Ltd director Lu Shao-Ta updated his initial ownership report through an amended Form 3. The amendment adds disclosure of 51,151 Ordinary Shares held indirectly through his spouse that were previously omitted from his original Form 3 and one subsequent Form 4. This change reflects a correction in reported holdings, not a new share transaction.
YD Bio Ltd director Lu Shao-Ta updated his initial ownership report through an amended Form 3. The amendment adds disclosure of 51,151 Ordinary Shares held indirectly through his spouse that were previously omitted from his original Form 3 and one subsequent Form 4. This change reflects a correction in reported holdings, not a new share transaction.
YD Bio Ltd director Lu Shao-Ta reported equity compensation activity involving restricted share units (RSUs) that settled into ordinary shares. On March 31, 2026, he received 2,081 RSUs for no cash cost, each representing a right to one ordinary share. The same day, these RSUs were exercised and converted into 2,081 ordinary shares at a conversion price of $0.00 per share, leaving him with 2,081 ordinary shares from this grant and no remaining RSUs from this tranche. The award is part of a broader $60,000 RSU grant under YD Bio’s equity incentive plan, scheduled to vest in four equal quarterly installments based on the stock’s seven‑day volume‑weighted average price before each vesting date.
YD Bio Ltd director Lu Shao-Ta reported equity compensation activity involving restricted share units (RSUs) that settled into ordinary shares. On March 31, 2026, he received 2,081 RSUs for no cash cost, each representing a right to one ordinary share. The same day, these RSUs were exercised and converted into 2,081 ordinary shares at a conversion price of $0.00 per share, leaving him with 2,081 ordinary shares from this grant and no remaining RSUs from this tranche. The award is part of a broader $60,000 RSU grant under YD Bio’s equity incentive plan, scheduled to vest in four equal quarterly installments based on the stock’s seven‑day volume‑weighted average price before each vesting date.
YD Bio Ltd director Chang Kochi reported equity compensation activity involving restricted share units. On March 31, 2026, Kochi received 2,081 restricted share units, each representing a right to one ordinary share.
The same day, 2,081 RSUs were exercised and converted into 2,081 ordinary shares at a price of $0.0000 per share, leaving 2,081 ordinary shares held directly after the transactions. The award was granted under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000, vesting in four equal quarterly installments of $15,000 each based on a seven trading-day volume-weighted average price.
YD Bio Ltd director Chang Kochi reported equity compensation activity involving restricted share units. On March 31, 2026, Kochi received 2,081 restricted share units, each representing a right to one ordinary share.
The same day, 2,081 RSUs were exercised and converted into 2,081 ordinary shares at a price of $0.0000 per share, leaving 2,081 ordinary shares held directly after the transactions. The award was granted under the YD Bio Limited Equity Incentive Plan with an aggregate target grant date fair value of $60,000, vesting in four equal quarterly installments of $15,000 each based on a seven trading-day volume-weighted average price.
YD Bio Ltd director Lu Shao-Ta has filed an initial Form 3 insider ownership report for YD Bio Ltd. The filing lists no reportable transactions or holdings, indicating this is an initial regulatory disclosure of insider status rather than a record of recent trading activity.
YD Bio Ltd director Chang Kochi filed an initial Form 3 reporting status as an insider of YD Bio Ltd (ticker YDES). The filing lists Kochi as a director and not a ten percent owner. No share transactions or derivative holdings are reported in this disclosure.
YD Bio Ltd director Chang Kochi filed an initial Form 3 reporting status as an insider of YD Bio Ltd (ticker YDES). The filing lists Kochi as a director and not a ten percent owner. No share transactions or derivative holdings are reported in this disclosure.
YD Bio Ltd director Lee Jerry Yin-Chia has filed a Form 3 insider report for YDES. The filing lists him as a director and indicates no reported purchases, sales, or other insider transactions, with all transaction counts and share totals recorded as zero.
YD Bio Ltd director Lee Jerry Yin-Chia has filed a Form 3 insider report for YDES. The filing lists him as a director and indicates no reported purchases, sales, or other insider transactions, with all transaction counts and share totals recorded as zero.
YD Bio Ltd executive Hen Man Edmund, the Chief Financial Officer, filed an initial ownership report on Form 3. This filing establishes his status as an insider of the company but does not report any purchases, sales, or other equity transactions.
YD Bio Ltd executive Hen Man Edmund, the Chief Financial Officer, filed an initial ownership report on Form 3. This filing establishes his status as an insider of the company but does not report any purchases, sales, or other equity transactions.
YD Bio Limited announced that its U.S. subsidiary, YD Bio USA, has entered a Master Strategic Alliance Agreement with YC Biotech to build a Taiwan-U.S. “Dual-Core” regulatory platform. YD Bio USA becomes YC Biotech’s exclusive U.S. Agent and formal liaison to the FDA for its Asian CRO clients.
The partnership covers a wide range of FDA interactions, including IND, NDA, BLA, IDE, 510(k), De Novo, and PMA submissions, as well as inspection readiness and ongoing regulatory strategy. YC Biotech will lead project acquisition and technical execution, while YD Bio USA handles U.S. regulatory interface and strategy.
The company describes this as a shift from single-project advisory work toward a scalable platform designed to onboard more Asian CRO partners, potentially expand to EMA-related work, and deepen a U.S. clinical network. Management notes that its pipeline already includes projects that have completed INTERACT, pre-IND, and IND meetings.
YD Bio Limited announced that its U.S. subsidiary, YD Bio USA, has entered a Master Strategic Alliance Agreement with YC Biotech to build a Taiwan-U.S. “Dual-Core” regulatory platform. YD Bio USA becomes YC Biotech’s exclusive U.S. Agent and formal liaison to the FDA for its Asian CRO clients.
The partnership covers a wide range of FDA interactions, including IND, NDA, BLA, IDE, 510(k), De Novo, and PMA submissions, as well as inspection readiness and ongoing regulatory strategy. YC Biotech will lead project acquisition and technical execution, while YD Bio USA handles U.S. regulatory interface and strategy.
The company describes this as a shift from single-project advisory work toward a scalable platform designed to onboard more Asian CRO partners, potentially expand to EMA-related work, and deepen a U.S. clinical network. Management notes that its pipeline already includes projects that have completed INTERACT, pre-IND, and IND meetings.
YD Bio Ltd files an amended Schedule 13G showing beneficial ownership stakes. The filing reports that Ethan Shen beneficially owns 54,345,011 ordinary shares (77.06%) and YD Biopharma Holding Limited beneficially owns 43,120,858 ordinary shares (61.15%). The filing states these percentages are calculated from a total of 70,521,359 ordinary shares as of November 17, 2025, per the issuer's Rule 424(b)(3) prospectus. The cover-page rows break ownership into sole and shared voting and dispositive powers, with Mr. Shen holding 11,224,153 sole voting and dispositive shares and 43,120,858 shared voting and dispositive shares through the Cayman Islands entity.
YD Bio Ltd files an amended Schedule 13G showing beneficial ownership stakes. The filing reports that Ethan Shen beneficially owns 54,345,011 ordinary shares (77.06%) and YD Biopharma Holding Limited beneficially owns 43,120,858 ordinary shares (61.15%). The filing states these percentages are calculated from a total of 70,521,359 ordinary shares as of November 17, 2025, per the issuer's Rule 424(b)(3) prospectus. The cover-page rows break ownership into sole and shared voting and dispositive powers, with Mr. Shen holding 11,224,153 sole voting and dispositive shares and 43,120,858 shared voting and dispositive shares through the Cayman Islands entity.